Biosimilars in Malaysia: Regulatory Framework, Approved Products, and Adverse Effects.
Noraisyah Mohd SaniZoriah AzizAdeeba KamarulzamanPublished in: Therapeutic innovation & regulatory science (2020)
Malaysia follows a stringent regulatory pathway for the approval of biosimilars enacted by well-established regulatory agencies to maintain the quality, efficacy and safety of biosimilars. Introducing biosimilars to the Malaysian market would improve patients' accessibility to biologic therapies.